Fulminant Myocarditis Induced By Immune Checkpoint Inhibitor Nivolumab

A Case Report and Review of the Literature

Feifei Wang; Yang Liu; Wei Xu; Changjing Zhang; Jianhong Lv; Shaolin Ma


J Med Case Reports. 2021;15(336) 

In This Article


In conclusion, fatal myocarditis may develop as an adverse event from the use of immune checkpoint inhibitors. Early recognition and prompt treatment are crucial for improving clinical outcomes. In this case, we suggest that ECMO should be considered in the management of fulminant myocarditis, the severe immune-related adverse effect associated with immune checkpoint inhibitors.